Filter
480
Filtered Results: 480
Text search:
Indian
Council
of
Medical
Research
India
Featured
Recommendations
27
New Publications
134
Language
Document type
No document type
298
Studies & Reports
85
Guidelines
44
Manuals
26
Training Material
12
Fact sheets
7
Resource Platforms
4
Strategic & Response Plan
4
Countries / Regions
India
186
Global
21
Asia
10
Nepal
9
South–East Asia Region
8
Uganda
6
South Africa
6
Bangladesh
6
Ukraine
6
Kenya
5
Myanmar / Burma
5
Philippines
4
Africa
4
Russia
4
Latin America and the Carribbean
3
Eastern Europe
3
Zimbabwe
2
Pakistan
2
Syria
2
Indonesia
2
Moldova
2
Liberia
1
Nigeria
1
Senegal
1
Morocco
1
Ghana
1
Lebanon
1
Zambia
1
Cambodia
1
Thailand
1
Malawi
1
Mozambique
1
Argentina
1
Peru
1
Brazil
1
North Macedonia
1
Hungary
1
Colombia
1
Mexico
1
Sri Lanka
1
East and Southern Africa
1
Western Pacific Region
1
Western and Central Europe
1
Poland
1
Estonia
1
Romania
1
Iran
1
Kyrgyzstan
1
Georgia
1
Jamaica
1
Maldives
1
Mauritius
1
Norway
1
Portugal
1
Authors & Publishers
Publication Years
Category
Countries
228
Clinical Guidelines
31
Public Health
29
Women & Child Health
12
Key Resources
11
Capacity Building
3
Pharmacy & Technologies
3
Toolboxes
Mental Health
46
TB
29
HIV
26
COVID-19
26
Disability
22
NCDs
20
AMR
16
NTDs
15
Global Health Education
13
Planetary Health
13
Pharmacy
13
Natural Hazards
12
Caregiver
12
Conflict
5
Refugee
5
Specific Hazards
5
Rapid Response
3
Health Financing Toolbox
3
Ebola
2
Polio
2
Zika
1
Social Ethics
1
COVAXINTM, India's indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council ... Medical Research (ICMR) - National Institute of Virology (NIV). The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) high containment facility.
The vaccine received DCGI approval for Phase I & II Human Clinical Trials and the trials commenced across India from July, 2020.
After successful completion of the interim analysis from the Phase 1 & 2 clinical trials of COVAXINTM, Bharat Biotech received DCGI approval for Phase 3 clinical trials in 26,000 participants in over 25 centres across India.
Prepared as an outcome of ICMR Subcommittee on Cancer Cervix | This consensus document on management of cervix cancer summarizes the modalities of ...
Prepared as an outcome of ICMR Subcommittee on Buccal Mucosa Cancer | This consensus document on management of Buccal Mucosa cancers summarizes the modalities ... treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular markers and research questions. It also interweaves clinical, biochemical and epidemiological studies.
These guidelines have been developed specifically to address ethical issues of conducting research in children.
Prepared as an outcome of ICMR Subcommittee on Colorectal Cancer | Coordinated by Division of Non Communicable Diseases | This Consensus Document on Management ... Colorectal Cancer summarizes the modalities of treatment including the site-specific anti-cancer therapies,
supportive and palliative care and molecular markers and research questions. It also interweaves clinical, biochemical and epidemiological studies.
Prepared as an outcome of ICMR Subcommittee on Esophageal Cancer | This consensus document on management of esophageal cancers
summarizes the modalities ... treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular markers and research questions. It also interweaves clinical, biochemical and epidemiological studies.
Prepared as an outcome of ICMR Subcommittee on Gastric Cancer | This consensus document on Management of Gallbladder cancers summarizes the modalities of<...
Full document available: https://www.icmr.nic.in/sites/default/files/guidelines/Gastric%20Cancer%20Final%20pdf%20for%20farrow_0.pdf | Prepared as an outcome of ICMR Subcommittee on Gastric Cancer | Coordinated by Division ... Non Communicable Diseases | This Consensus Document on Management of Gastric Cancers summarizes the modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular markers and research questions. It also interweaves clinical, biochemical and epidemiological studies.
Prepared as an outcome of ICMR Subcommittee on Larynx & Hypopharynx Cancers | This consensus document on management of larynx and hypopharynx cancers summarizes the modalities ... treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular markers and research questions. It also interweaves clinical, biochemical and epidemiological studies.
Prepared as an outcome of ICMR Subcommittee on Multiple Myeloma | This consensus document on management of multiple myeloma summarizes the modalities of...
Prepared as an outcome of ICMR Subcommittee on Non Hodgkin’s Lymphoma (High Grade) | This consensus document on management of non- hodgkin’s lymphoma – high grade summarizes the modalities ... treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular markers and research questions. It also interweaves clinical, biochemical and epidemiological studies.
Prepared as an outcome of ICMR Subcommittee on Soft Tissue Sarcoma and Osteosarcoma | This consensus document on Management of Soft Tissue Sarcoma and Osteosarcoma summarizes the modalities ... treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular markers and research questions. It also interweaves clinical, biochemical and epidemiological studies.
Prepared as an outcome of ICMR Expert Group on Immunophenotyping of Hematolymphoid Neoplasms | Coordinated by Division of Non Communicable Diseases...
These guidelines will assist the ICMR institutions/ centers/ Hqrs. by providing information on the policies, principles and approaches which should be followed in carrying out procurement of goods and services at their respective institute/ center/ ...
These guidelines have been developed for scientific purpose with the main aim to guide the regulatory authority for evaluating probiotic products in our country.
These Guidelines are intended to provide knowledge to the treating ophthalmologists, pediatricians, ocular oncologists, pediatric oncologists, and general physicians to arrive at an early diagnosis of retinoblastoma in the settings ... district hospital, in private clinics and hospitals. The guidelines will enable the contact health personnel to refer at the right
time to the tertiary care hospital for management of retinoblastoma.
